📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 15:56
690 analysed today
690
Today
133,579
All-time analysed
40,122
Positive
6,284
Negative
79,354
Neutral
7,751
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Rs 12.05 Lacs Net Loss in Q1 FY27; Revenue at Rs 66.85 Lacs
Rekvina Laboratories reported a net loss of Rs 12.05 Lacs for the quarter ended June 30, 2026, widening from a loss of Rs 3.54 Lacs in the year-ago period. While revenue from operations grew to Rs 66.85 Lacs from zero in Q1 FY26, it declined sequentially from Rs 72.36 Lacs in Q4 FY26. Total expenses of Rs 78.90 Lacs outpaced income, primarily due to stock-in-trade purchases of Rs 69.76 Lacs. The company also appointed Executive Director Surbhit Shah as the new Chairman of the Board.
Confidence: HIGH
What changedThe company reported its first-quarter results for FY27, showing a resumption of revenue compared to the previous year but continued net losses and a change in board leadership.
Why it mattersWith a market cap of only Rs 42 Cr and negative net worth, the company's inability to reach operational break-even despite revenue growth poses a significant solvency risk.
Revenue (Q1 FY27): Rs 66.85 LacsNet Loss (Q1 FY27): Rs 12.05 LacsQ1 Revenue vs TTM Revenue: 66.85%Net Worth: Rs -1 CrPromoter Holding: 41.3%
📅 Short termThe stock may face pressure due to widening losses and the small scale of operations relative to its negative net worth.
📈 Long termLimited; the company needs a significant capital infusion or a major operational turnaround to address its negative equity and consistent losses.
⚠ Risk flags
- Negative net worth
- Consistent operational losses
- Micro-cap liquidity risk
- High negative ROCE
Key Highlights
Net loss widened to Rs 12.05 Lacs in Q1 FY27 compared to a loss of Rs 3.54 Lacs in Q1 FY26
Revenue from operations stood at Rs 66.85 Lacs, up from Nil in the corresponding quarter last year
Total expenses rose to Rs 78.90 Lacs, with stock-in-trade purchases accounting for 88% of total costs
Earnings Per Share (EPS) remained negative at -Rs 0.20 for the quarter
Executive Director Surbhit Shah appointed as Chairman effective August 13, 2026
👀 What to Watch
Investors should monitor the company's ability to scale revenue to a level that covers fixed costs, as the current net worth remains negative at Rs -1 Cr.
Rekvina Laboratories Q1 Net Loss Widens to ₹12.05 Lacs; Revenue at ₹66.85 Lacs
Rekvina Laboratories reported a net loss of ₹12.05 Lacs for the quarter ended June 30, 2026, compared to a loss of ₹6.05 Lacs in the previous quarter. Revenue from operations stood at ₹66.85 Lacs, a sequential decline of 7.6% from ₹72.36 Lacs in Q4 FY26. The company continues to struggle with profitability, reporting a negative ROCE of -333.3% and a negative net worth of ₹1 Cr. Additionally, the board appointed Executive Director Mr. Surbhit Shah as the Chairman.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results showing widening losses and appointed a new Chairman of the Board.
Why it mattersThe company is operating with a negative net worth and persistent losses, which raises concerns about its long-term financial viability and operational sustainability.
Revenue (Q1 FY27): ₹66.85 LacsNet Loss (Q1 FY27): ₹12.05 LacsQ1 Revenue vs TTM Revenue: ~67%Net Worth: ₹-1 CrEPS (Q1 FY27): -0.20
📅 Short termThe widening loss and sequential revenue decline are likely to weigh negatively on investor sentiment in the short term.
📈 Long termThe long-term outlook remains challenging given the negative net worth and lack of operational profitability; a significant turnaround or capital infusion is required.
⚠ Risk flags
- Negative net worth
- Widening quarterly losses
- Micro-cap liquidity risk
- Negative ROCE
Key Highlights
Revenue from operations reached ₹66.85 Lacs in Q1 FY27, compared to zero revenue in the same quarter last year.
Net loss widened to ₹12.05 Lacs from ₹6.05 Lacs in the preceding quarter (QoQ).
Total expenses for the quarter were ₹78.90 Lacs, which exceeded the total income of ₹66.85 Lacs.
Purchases of stock-in-trade accounted for ₹69.76 Lacs, representing 88% of total expenses.
Appointment of Mr. Surbhit Shah as Chairman of the Board of Directors.
👀 What to Watch
Investors should monitor the company's ability to scale revenue to a level that covers fixed costs and observe if the new leadership can address the negative net worth situation.
Rekvina Labs acquires Radiant Parenterals for ₹4.63 Cr; Target revenue is 31x Rekvina's TTM revenue
Rekvina Laboratories has approved the allotment of 50.88 lakh equity shares at ₹10 per share to acquire 100% of Radiant Parenterals Limited and raise cash. The acquisition is valued at ₹4.63 crore via a share swap, while ₹0.46 crore was raised through a cash allotment. This is a transformative deal as Radiant Parenterals reported FY25 revenue of ₹31.67 crore, which is approximately 31.7 times Rekvina's TTM revenue of ₹1 crore. Post-acquisition, Radiant becomes a wholly-owned subsidiary, bringing WHO-GMP certified manufacturing capabilities for injectables and syrups into the company.
Confidence: HIGH
What changedRekvina has completed the share allotment to fully acquire Radiant Parenterals Limited, effectively scaling its business operations from a near-dormant state to an active manufacturer.
Why it mattersThis acquisition fundamentally changes Rekvina's financial profile, replacing a ₹1 Cr revenue base with a ₹30 Cr+ revenue operation, though it comes at the cost of significant equity dilution.
Acquisition Value: ₹4.63 CrTarget Revenue (FY25): ₹31.67 CrTarget Revenue vs Rekvina TTM Revenue: 31.67xTotal Shares Allotted: 50,87,750Issue Price per Share: ₹10
📅 Short termThe market is likely to react positively to the massive jump in inorganic revenue and the addition of certified manufacturing assets.
📈 Long termIf the company successfully integrates Radiant and maintains its growth trajectory (from ₹0.77 Cr to ₹31.67 Cr in two years), this could represent a total structural re-rating of the stock.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant equity dilution
- Integration risk of a much larger entity
- Target revenue has shown extreme volatility (₹0.77 Cr to ₹31.67 Cr in 24 months)
Key Highlights
Acquisition of 100% stake (18,51,100 shares) in Radiant Parenterals Limited for a total consideration of ₹4.63 crore.
Radiant Parenterals FY25 revenue stood at ₹31.67 crore, showing massive growth from ₹0.77 crore in FY23.
Allotment of 46,27,750 shares via share swap and 4,60,000 shares for cash, all at ₹10 per share (including ₹5 premium).
Target company operates a WHO-GMP & ISO 9001-2015 certified unit in Vadodara specializing in anti-hypertensive and anti-diabetic products.
Significant increase in promoter-linked shareholding, with two key investors moving from a combined 28.95% to 49.33% stake.
👀 What to Watch
Watch for the first consolidated quarterly results to see how Radiant's ₹31.67 Cr revenue base impacts Rekvina's bottom line and negative net worth.
77.33% Promoter Stake Post-Open Offer at ₹10/Share for Rekvina Laboratories
The open offer for Rekvina Laboratories by Surbhit Mukesh Shah and others concluded with 14,41,863 shares accepted at ₹10 each, totaling ₹1.44 Cr. This acquisition, combined with a share swap agreement (SEPA), will result in the promoter group holding 77.33% of the expanded share capital. The offer price of ₹10 is at a significant discount to the current market price of ₹25.2. The company remains financially stressed with a negative net worth of ₹1 Cr and TTM revenue of only ₹1 Cr.
Confidence: HIGH
What changedThe open offer process has concluded, finalizing the consolidation of control by the new promoter group and establishing the post-offer shareholding structure.
Why it mattersThis represents a major change in control and ownership for a micro-cap company. With the promoter stake rising to 77.33%, the new management's ability to revive the pharmaceutical business is the primary factor for future valuation.
Offer Price: ₹10Actual Shares Accepted: 14,41,863Post-Offer Promoter Holding: 77.33%Offer Value vs Market Cap: ~4.5%TTM Revenue: ₹1 Cr
📅 Short termThe stock may see limited liquidity as the public float has dropped to 23%. The wide gap between the ₹10 offer price and the current market price may create volatility.
📈 Long termThe company's long-term prospects depend entirely on the new promoters' ability to scale the pharma business from its current negligible base and repair the negative net worth.
⚠ Risk flags
- Negative net worth of ₹1 Cr
- Promoter holding exceeds 75% limit
- Extremely low revenue scale (₹1.27 Cr FY26)
- Significant discount of offer price to market price
Key Highlights
14,41,863 shares accepted in the open offer at a price of ₹10 per share
Total consideration paid for the open offer shares amounted to ₹1.44 Cr
Promoter group holding to reach 77.33% of expanded share capital post-transaction
Public shareholding reduced significantly from 58.70% to 23.00%
Underlying transaction involves a share swap of 46,27,750 equity shares at ₹10 each
👀 What to Watch
Monitor the company's operational turnaround under the consolidated promoter group, as the current financials show negative net worth and minimal revenue. Investors should also note that the promoter holding now exceeds the 75% regulatory limit, necessitating a future dilution to meet Minimum Public Shareholding (MPS) norms.
77.33% Post-Offer Promoter Holding as Rekvina Laboratories Completes Open Offer at ₹10
The open offer for Rekvina Laboratories has concluded with the acquirer group (Surbhit Shah, Amit Shah, and Dhruvalkumar Patel) acquiring 14,41,863 shares at ₹10 per share. This represents approximately 12.97% of the expanded share capital, significantly lower than the 26% originally sought, likely due to the offer price being at a steep discount to the market price. Post-transaction, the total promoter and acquirer group holding has reached 77.33%, while public shareholding has dropped to 23.00%. The acquisition follows a share swap agreement involving Radiant shares valued at ₹25.
Confidence: HIGH
What changedThe company has undergone a change in control with a new acquirer group now holding a 77.33% majority stake following the completion of an open offer and share swap agreement.
Why it mattersFor a micro-cap company with stressed financials (negative net worth and ROCE), a change in promoter group is a critical event that could lead to capital infusion or a change in business direction.
Offer Price: ₹10Actual Shares Accepted: 14,41,863Post-Offer Promoter Group Holding: 77.33%Post-Offer Public Holding: 23.00%Offer Price vs Current Price: -60.5%
📅 Short termThe stock may experience volatility as the market processes the new shareholding structure and the breach of the 25% minimum public shareholding limit.
📈 Long termThe long-term outlook is entirely dependent on the new promoters' ability to scale operations from the current ₹1 Cr revenue base and repair the negative net worth.
⚠ Risk flags
- Breach of Minimum Public Shareholding (25%)
- Negative Net Worth (₹-1 Cr)
- Extremely low operational scale (TTM Revenue ₹1 Cr)
- Significant discount of offer price to market price
Key Highlights
Acquirers accepted 14,41,863 equity shares out of the 28,90,100 shares proposed in the open offer.
Post-offer promoter and acquirer group holding stands at 77.33%, exceeding the 75% threshold usually permitted.
The open offer price was ₹10 per share, which is a 60.5% discount to the current market price of ₹25.3.
Public shareholding has been reduced from 58.70% to 23.00% following the offer and underlying transactions.
The total actual offer size was ₹1.44 Cr compared to the proposed ₹2.89 Cr.
👀 What to Watch
Investors should monitor the company's plan to comply with the Minimum Public Shareholding (MPS) requirement of 25%, as the current public holding is 23%. Additionally, watch for any business turnaround plans from the new management given the company's negative net worth of ₹-1 Cr and low TTM revenue of ₹1 Cr.
